From the Journals News

Imetelstat for RBC Transfusion Independence in Lower-Risk Myelodysplastic Syndromes

December 21, 2023 By Matthew Stenger 2 min read
Share Share via Email Share on Facebook Share on LinkedIn Share on X

As reported in The Lancet by Uwe Platzbecker, MD, and colleagues, the phase III IMerge trial has shown improved red blood cell transfusion independence with imetelstat, a competitive telomerase inhibitor, vs placebo in RBC transfusion-dependent patients with lower-risk myelodysplastic syndromes who did not respond to or were ineligible for erythropoiesis-stimulating agents.

Uwe Platzbecker, MD
Uwe Platzbecker, MD

In the double-blind trial, 178 patients from sites in 17 countries were randomly assigned 2:1 between September 2019 and October 2021 to receive imetelstat at 7.5 mg/kg (n = 118) or placebo (n = 60) every 4 weeks until disease progression or unacceptable toxicity. The primary endpoint was 8-week RBC transfusion independence in the intent-to-treat population.

RBC Transfusion Independence

Median follow-up was 19.5 months (interquartile range = 12.0–23.4 months) in the imetelstat group and 17.5 months (IQR = 12.1–22.7) in the placebo group. RBC transfusion independence for ≥ 8 weeks was observed in 47 patients (40%, 95% confidence interval [CI] = 30.9%–49.3%) in the imetelstat group vs 9 patients (15%, 95% CI = 7.1%–26.6%) in the placebo group (rate difference = 25%, 95% CI = 9.9%–36.9%, P = .0008).

Continuous RBC transfusion independence for ≥ 24 weeks was observed in 33 patients (28%, 95% CI = 20.1%–37.0%) in the imetelstat group vs 2 patients (3%, 95% CI = 0.4%–11.5%) in the placebo group (rate difference = 25%, 95% CI = 12.6%–34.2%, P = .0001).

Among patients with RBC transfusion independence for ≥ 8 weeks, median duration of RBC transfusion independence was 51.6 weeks (95% CI = 26.9–83.9 weeks) in the imetelstat group vs 13.3 weeks (95% CI = 8.0–24.9 weeks) in the placebo group (hazard ratio = 0.23, 95% CI = 0.09–0.57).

Adverse Events

Grade 3 or 4 adverse events occurred in 91% of patients in the imetelstat group vs 47% of the placebo group. The most common in the imetelstat group were neutropenia (68%), thrombocytopenia (62%), and anemia (19%); the most common in the placebo group were thrombocytopenia (8%) and anemia (7%). Serious adverse events occurred in 32% vs 22% of patients. Adverse events leading to discontinuation of imetelstat included neutropenia (5%) and thrombocytopenia (3%). No treatment-related deaths were reported.

The investigators concluded, “Imetelstat offers a novel mechanism of action with durable transfusion independence (approximately 1 year) and disease-modifying activity for heavily transfused patients with lower-risk myelodysplastic syndromes who are not responding to or are ineligible for erythropoiesis-stimulating agents.”

Uwe Platzbecker, MD, of the Department of Hematology, Cellular Therapy, Infectious Diseases, and Hemostaseology, University Hospital Leipzig, is the corresponding author for The Lancet article.

Disclosure: The study was funded by Janssen Research & Development before April 18, 2019, and Geron Corporation thereafter. For full disclosures of the study authors, visit thelancet.com.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.